• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

ViroGates publishes its half-year report for the first half of 2026 on 20 August and invites to a webinar on 21 August 2026

VIROPressemeddelelse18.08.2026, 11.02

Company Announcement no. 8/2026 (August 18, 2026)

For immediate release

BIRKERØD, DENMARK – ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring chronic inflammation at health clinics and hospitals, will be publishing its half-year report covering the period 1 January 2026 to 30 June 2026 on Thursday 20th August 2026.

The half-year report will be published on the Company’s website at www.virogates.com and distributed via Nasdaq First North Growth Market Denmark and other media channels.

Following the publication, ViroGates invites shareholders, investors, and other interested parties to a live webinar on Friday, 21 August 2026, at 11:00, where CEO Jakob Knudsen and CFO Josephine Baum Jørgensen will present the results for the first half of 2026 and provide an update on the Company’s strategy and outlook. The presentation will be followed by a Q&A session.

You can sign up for the event using the link below and post questions in advance of the presentation.

Date: Friday, 21 August 2026
Time: 11:00 CET
Host: Stokk.io
Link: https://app.stokk.io/app/virogates/event/234/h1-presentation-and-qa/

A recording of the presentation will subsequently be made available on the Company’s website.

For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:
Västra Hamnen Corporate Finance AB
Per Lönn
Tel. (+46) 40 200 250 | Email: per.lonn@vhcorp.se

About ViroGates
ViroGates A/S is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals to improve hospital patient care. ViroGates markets its blood test products under the suPARnostic® brand.

The company was founded in 2000. Headquartered in Denmark, ViroGates sells directly to markets across the EU and the rest of the world, complemented by a network of distributors covering selected markets. ViroGates’ shares (ticker “VIRO”) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

Attachments
20260818 PR ViroGates Ann 8 H1 Date And Webinar